Table 2.

The enriched V_H replacement products encoding anti-HIV antibodies are highly mutated.

	Sequence ID	VH Name	VH (nt)	Mutations (nt)	Mutation Rate (%)	Replacement (nt)	Silent (nt)	R/S ratio
Anti-gp41	EU794402	IGHV1-69	294	49	16.67	33	16	2.06
	EU794399	IGHV1-69	295	44	14.92	33	11	3.00
Anti-V3 loop	EU794433	IGHV3-7	293	35	11.95	27	8	3.38
	EU794439	IGHV4-59	288	32	11.11	19	13	1.46
	EU794437	IGHV5-51	294	20	6.80	19	1	19.00
	EU794436	IGHV1-18	295	36	12.20	28	8	3.50
	EU794422	IGHV4-59	291	24	8.25	19	5	3.80
	S77136	IGHV3-11	295	29	9.83	22	7	3.14
	EU794425	IGHV2-5	297	20	6.73	12	8	1.50
	EU794427	IGHV5-51	293	10	3.41	8	2	4.00
	EU794414	IGHV5-51	294	20	6.80	17	3	5.67
Anti-gp120	Z35118	IGHV2-26	299	11	3.68	9	2	4.50
	Z35126	IGHV4-31	298	11	3.69	4	7	0.57
	U82950	IGHV1-69	290	32	11.03	26	6	4.33
	AF086903	IGHV3-30	294	16	5.44	13	3	4.33
	U82767	IGHV1-69	292	45	15.41	32	13	2.46
	S67982	IGHV1-69	291	29	9.97	24	5	4.80
	S67984	IGHV2-5	292	8	2.74	4	4	1.00
	U82942	IGHV1-69	294	32	10.88	24	8	3.00
CD4i	17b	IGHV1-69	295	34	11.53	28	6	4.67
	c12	IGHV1-69	296	27	9.12	20	7	2.86
	23e	IGHV1-69	295	21	7.12	13	8	1.63
	M16	IGHV1-69	292	44	15.07	32	12	2.67
	SB1	IGHV1-69	292	24	8.22	16	8	2.00
	X5	IGHV1-69	296	27	9.12	21	6	3.50
	47e	IGHV1-69	295	9	3.05	7	2	3.50
	E51	IGHV1-69	293	27	9.22	20	7	2.86
PGT	PGT121H	IGHV4-59	291	56	19.24	38	18	2.11
	PGT122H	IGHV4-61	295	56	18.98	37	19	1.95
	PGT123H	IGHV4-59	288	64	22.22	42	22	1.91
	PGT125H	IGHV4-b	277	106	38.27	97	9	10.78
	PGT126H	IGHV4-b	277	105	37.91	97	8	12.13
	PGT127H	IGHV4-61	280	99	35.36	91	8	11.38
	PGT128H	IGHV4-b	277	112	40.43	107	5	21.40
	PGT130H	IGHV4-39	297	63	21.21	49	14	3.50
	PGT131H	IGHV4-39	297	65	21.89	49	16	3.06
	PGT135H	IGHV4-34	219	59	26.94	47	12	3.92
	PGT136H	IGHV4-39	196	46	23.47	40	6	6.67
	PGT137H	IGHV4-39	196	56	28.57	47	9	5.22
	PGT141H	IGHV1-8	296	47	15.88	37	10	3.70
	PGT142H	IGHV1-8	296	48	16.22	38	10	3.80
	PGT143H	IGHV1-8	296	47	15.88	36	11	3.27
	PGT144H	IGHV1-8	296	51	17.23	42	9	4.67
	PGT145H	IGHV1-8	296	52	17.57	40	12	3.33